Drug firm Zydus Cadila today said it has received final approval from the US health regulator to market Pindolol tablets, used for the treatment of hypertension.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 5 mg and 10 mg, Zydus Cadila said in a BSE filing.
Pindolol belongs to a class of beta-blockers and is used to treat hypertension.
The company said it will manufacture the drug at the group’s manufacturing facility in the Pharma SEZ in Ahmedabad.
The company has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of the company’s listed entity, Cadila Healthcare, were trading 0.89 per cent down at Rs 468.85 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.